Join Growin Stock Community!

Biocryst pharmaceuticals, inc.BCRX.US Overview

US StockHealthcare
(No presentation for BCRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCRX AI Insights

BCRX Overall Performance

BCRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCRX Recent Performance

-0.95%

Biocryst pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BCRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCRX Key Information

BCRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCRX Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Price of BCRX

BCRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.25
PE Ratio (TTM)
-
Forward PE
38.41
PS Ratio (TTM)
3.65
PB Ratio
56.59
Price-to-FCF
5.29
METRIC
VALUE
vs. INDUSTRY
Gross Margin
97.82%
Net Margin
30.16%
Revenue Growth (YoY)
94.10%
Profit Growth (YoY)
95.28%
3-Year Revenue Growth
72.25%
3-Year Profit Growth
72.72%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.25
PE Ratio (TTM)
-
Forward PE
38.41
PS Ratio (TTM)
3.65
PB Ratio
56.59
Price-to-FCF
5.29
Gross Margin
97.82%
Net Margin
30.16%
Revenue Growth (YoY)
94.10%
Profit Growth (YoY)
95.28%
3-Year Revenue Growth
72.25%
3-Year Profit Growth
72.72%

  • When is BCRX's latest earnings report released?

    The most recent financial report for Biocryst pharmaceuticals, inc. (BCRX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCRX's short-term business performance and financial health. For the latest updates on BCRX's earnings releases, visit this page regularly.

  • What is the operating profit of BCRX?

    According to the latest financial report, Biocryst pharmaceuticals, inc. (BCRX) reported an Operating Profit of 260.39M with an Operating Margin of 64.05% this period, representing a growth of 5,876.06% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BCRX's revenue growth?

    In the latest financial report, Biocryst pharmaceuticals, inc. (BCRX) announced revenue of 406.56M, with a Year-Over-Year growth rate of 209.09%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BCRX have?

    As of the end of the reporting period, Biocryst pharmaceuticals, inc. (BCRX) had total debt of 477.33M, with a debt ratio of 0.93. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BCRX have?

    At the end of the period, Biocryst pharmaceuticals, inc. (BCRX) held Total Cash and Cash Equivalents of 89.94M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BCRX go with three margins increasing?

    In the latest report, Biocryst pharmaceuticals, inc. (BCRX) achieved the “three margins increasing” benchmark, with a gross margin of 97.7%%, operating margin of 64.05%%, and net margin of 60.5%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BCRX's profit trajectory and future growth potential.

  • Is BCRX's EPS continuing to grow?

    According to the past four quarterly reports, Biocryst pharmaceuticals, inc. (BCRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.17. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BCRX?

    Biocryst pharmaceuticals, inc. (BCRX)'s Free Cash Flow (FCF) for the period is 291.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 5,044.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.